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Abstract
Hearing loss and impaired fertility are common human disorders each with multiple genetic causes. Sometimes deafness 
and impaired fertility, which are the hallmarks of Perrault syndrome, co-occur in a person. Perrault syndrome is inherited 
as an autosomal recessive disorder characterized by bilateral mild to severe childhood sensorineural hearing loss with vari-
able age of onset in both sexes and ovarian dysfunction in females who have a 46, XX karyotype. Since the initial clinical 
description of Perrault syndrome 70 years ago, the phenotype of some subjects may additionally involve developmental delay, 
intellectual deficit and other neurological disabilities, which can vary in severity in part dependent upon the genetic variants 
and the gene involved. Here, we review the molecular genetics and clinical phenotype of Perrault syndrome and focus on 
supporting evidence for the eight genes (CLPP, ERAL1, GGPS1, HARS2, HSD17B4, LARS2, RMND1, TWNK) associated 
with Perrault syndrome. Variants of these eight genes only account for approximately half of the individuals with clinical 
features of Perrault syndrome where the molecular genetic base remains under investigation. Additional environmental eti-
ologies and novel Perrault disease-associated genes remain to be identified to account for unresolved cases. We also report 
a new genetic variant of CLPP, computational structural insight about CLPP and single cell RNAseq data for eight reported 
Perrault syndrome genes suggesting a common cellular pathophysiology for this disorder. Some unanswered questions are 
raised to kindle future research about Perrault syndrome.
Introduction
Seventy years ago, M. Perrault described a rare multisystem 
disorder of deafness and infertility in two sisters (Josso et al. 
1963; Pallister and Opitz 1979; Perrault et al. 1951). Since 
then, more cases of Perrault syndrome have been reported 
and it is now recognized as a clinically and genetically het-
erogenous sex-influenced disorder that has an autosomal 
recessive mode of inheritance (Demain et al. 2017; Newman 
et al. 2018). Perrault syndrome is characterized in females 
by moderate to profound sensorineural hearing loss with 
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variable age of onset, usually the initial finding, a range of 
ovarian dysfunction with the most severe being the absence 
of ovaries despite a normal 46,XX karyotype. When ovaries 
are absent, estrogens are present at significantly lower lev-
els, secondary sex characteristics are under-developed, and 
gonadotropins are elevated. A usual presentation of Perrault 
syndrome is a bilateral hearing loss, primary amenorrhea 
and a hormone profile consistent with hypergonadotropic 
hypogonadism or primary ovarian insufficiency (POI) char-
acterized by menses cessation before the fourth decade of 
life (Newman et al. 2018). In some families with females 
affected by Perrault syndrome, the deaf males were not 
tested for fertility, there were no deaf males or the males are 
prepubertal (Jenkinson et al. 2013; Newman et al. 2018). 
Perrault syndrome may not be suspected when a deaf pre-
pubertal female is ascertained and only her hearing abil-
ity is evaluated. Males with pathogenic variants in Perrault 
syndrome genes, without affected female siblings, are now 
being ascertained due to the increased application of genetic 
testing, including exomes and large panels of genes associ-
ated with hearing loss. A pre-pubertal deaf female seeking 
an explanation for her hearing loss, but lacking a molecular 
diagnosis, may not have an ovarian dysfunction noticed by 
an astute clinician or by the patient until after the expected 
onset of puberty. Similarly, the increased use of genetic test-
ing for presumed isolated deafness can identify pre-puber-
tal females with a possible diagnosis of Perrault syndrome 
before ovarian dysfunction has presented clinically.
Two clinical classifications of Perrault syndrome have 
been proposed (Fiumara et al. 2004; Newman et al. 2018; 
Pierce et al. 2010). Both Type 1 and Type 2 include the 
two cardinal signs of sensorineural hearing loss and POI. 
For the Type 2 subgroup of Perrault syndrome, there is a 
more complex presentation that may include intellectual 
disability, progressive sensory disorders or motor neuropa-
thies. In some of the Type 2 cases, there is reluctance to 
necessarily assume that the additional neurological features 
are the direct result of the variants associated with the clas-
sical features of Perrault syndrome rather than coincidental 
clinical findings (Demain et al. 2018; Fiumara et al. 2004; 
Gottschalk et al. 1996). In both Type 1 and Type 2 Perrault 
syndrome, estrogen levels are decreased while the gonado-
tropins luteinizing hormone (LH) and follicle stimulating 
hormone (FSH) are significantly elevated. The two clini-
cal subtypes (Type 1 and 2) of Perrault syndrome should 
not be confused with the consecutive number types on the 
Online Mendelian Inheritance of Man (OMIM) that have 
been assigned to each gene with variants associated with 
Perrault syndrome.
In this review we focus on genes where variants result 
in a clinical presentation of POI and SNHL as the primary 
features while acknowledging that more deleterious variants 
in these same genes can lead to more severe clinical presen-
tations. We excluded from discussion genes where variants 
are associated with a broad spectrum of clinical features 
which include POI and SNHL. The genetic bases of Perrault 
syndrome involve recessive pathogenic variants of at least 
eight different genes described below and in Fig. 1. In many 
of the reported cases of Perrault syndrome the phenotype 
is variable within a family suggesting environmental influ-
ences, modifier variants in the genetic background or both. 
Seven of the eight genes with autosomal recessive variants 
associated with Perrault syndrome encode mitochondrial 
proteins while HSD17B4 is a peroxisomal protein.
CLPP
The CLPP gene is located on human chromosome 19p13 and 
encodes caseinolytic peptidase proteolytic subunit (Jenkin-
son et al. 2013). Molecular genetic data in human and mouse 
models support the conclusion that recessive variants of 
CLPP result in Perrault syndrome Type 1 or Type 2 (Fig. 1). 
The primary sequence of the nascent CLPP protein has a 
N-terminus mitochondrial import sequence. The mature 
CLPP monomer multimerizes in the mitochondrial matrix 
to form a heptamer that docks with CLPXP (AAA + family 
member caseinolytic peptidase X) forming a tetradecamer 
(CLPP-CLPX) necessary in this organelle for proteostasis. 
Regulated ATP-dependent degradation of a subset of mito-
chondrial proteins for quality control and regulation of trans-
lation occurs when a protein is recognized by the hexameric 
ring of CLPX, which unfolds and translocates the protein 
strand through the axial pore of the tetradecamer into the 
barrel-shaped chamber enclosing 14 peptidase active sites 
(Brodie et al. 2018; Flanagan et al. 1995; Kang et al. 2004; 
Wang et al. 1997).
Fig. 1  The eight genes to date reported to be associated with Per-
rault syndrome, their pathogenic variants and locations in the exons 
or introns of these genes. There are two published deletions of CLPP 
that are in compound heterozygosity with amino acid substitutions. 
Deletion 1 was reported to be in trans to p.G162S while deletion 2 
was in trans to p.P142L (Theunissen et  al. 2016). For HARS2, # 
indicates variants that are associated with sensorineural hearing loss 
(Supplementary Table  1 for all reported variants and references). 
The ## for a variant of HSD17B4 indicates an association with pre-
mature ovarian failure while D/PS indicates variants associated with 
d-bifunctional protein deficiency/Perrault syndrome Type 1. The 
p.R663W variant of LARS2 was previously associated with Intel-
lectual Disability (Cherot et al. 2018) although the same variant was 
reported for Perrault syndrome (Tucker et al. 2020). The homozygous 
N238S variant of RMND1 is associated with a Perrault-like syn-
drome with renal defects. Interestingly, the same variant in compound 
heterozygosity with p.Gln189* or c.613G > T is associated with 
a more severe phenotype that also includes chronic kidney disease, 
dilated cardiomyopathy, neurological involvement, neonatal lactic 
acidosis and deafness (Broenen et al. 2019; Gupta et al. 2016; Janer 




Multiple crystal structures of CLPP from several organ-
isms reveal a conserved architecture (Gottesman 1996; 
Jenkinson et al. 2013; Szyk and Maurizi 2006). The struc-
tures of CLPP were then used to deduce possible functional 
impairments caused by pathogenic missense variants of 
human CLPP associated with Perrault syndrome (Brodie 
et al. 2018; Jenkinson et al. 2013). CLPP was first identi-
fied as a Perrault syndrome gene in three consanguineous 
families with profound deafness. In two of the three fami-
lies, deaf females were diagnosed with POI. Genetic link-
age analyses of the deafness phenotype revealed a locus on 
chromosome 19. Subsequently, the families were found to be 
segregating two different homozygous missense variants and 
a homozygous splice site variant. Hormonal profiles were 
evaluated for some of the deaf females and imaging of the 
ovaries were performed (Jenkinson et al. 2013). In family 
PDF1, one affected female had two male children. Notably 
she had a premature menopause at 23 years, consistent with 
ovarian insufficiency. One of her affected sisters had second-
ary amenorrhea whereas the other had streak ovaries and 
hypergonadotropic hypogonadism. All three sisters in this 
family have epilepsy, short stature, microcephaly and mild 
learning disability. Four affected females of a second family 
had primary amenorrhea, hypergonadotropic hypogonadism, 
rudimentary uteruses and small ovaries by ultrasonography 
(Jenkinson et al. 2013). To date, there are 13 different vari-
ants associated with Perrault syndrome that affect single 
base pairs of CLPP and two intragenic deletions of CLPP 
(Fig. 1) (Theunissen et al. 2016). Damaging variants of the 
eight genes associated with Perrault syndrome (Fig. 1) are 
either absent or at low frequency in the public human vari-
ant databases.
Individuals diagnosed with Perrault syndrome who have 
biallelic variants of CLPP (Fig. 1) are usually profoundly 
deaf. This hearing loss phenotype could be an ascertain-
ment bias (Jenkinson et al. 2013) as individuals who are 
profoundly deaf are more likely to undergo genetic test-
ing than individuals with more modest impairment. Here, 
we describe a homozygous missense variant of CLPP that 
results in moderate to severe hearing loss in an individual 
diagnosed with Perrault syndrome (Fig. S1). The homozy-
gous p.T135S missense variant of CLPP is segregating in a 
consanguineous Pakistani family (HLZM05) with a proband 
who is an 18-year-old woman reporting childhood onset 
bilateral sensorineural moderate to severe hearing loss simi-
lar to the auditory phenotype of her 20-year-old brother. She 
had primary amenorrhea and self-reports that her secondary 
sexual characteristics are underdeveloped. Taken together, 
the p.T135S variant of CLPP segregating in family HLZM05 
is associated with Type 1 Perrault syndrome with a moderate 
to severe hearing loss.
Variants that are null alleles or severely disable CLPP 
function result in more severe cases of Perrault syndrome. 
For instance, two severely affected siblings were homozy-
gous for a frameshift variant (c.21delA) in exon 1 of CLPP 
(premature translation stop codon in exon 3) predicted to 
truncate 160 residues (Theunissen et al. 2016). The authors 
demonstrated that the c.21delA allele causes nonsense medi-
ated decay of CLPP mRNA. The phenotype of the affected 
siblings included small stature, congenital sensorineu-
ral deafness, psychomotor retardation, ataxia, autism and 
epilepsy. Brain-MRI signal abnormalities were observed 
in the subcortical and deep cerebral white matter. Similar 
leukoencephalopathies were reported in three other patients 
with variants of CLPP one of whom was hemizygous for 
a missense mutation (G162S) predicted to destabilize and 
disrupt CLPP structure. This missense variant was in trans 
to a deletion (Fig. 1) inherited from the healthy mother that 
spanned exons 3 and 4 of CLPP (Theunissen et al. 2016).
CLPP protein is readily detected in mitochondria of 
human ovarian germ cells but was not detected in the stromal 
layers (Jenkinson et al. 2013) while in mouse ovaries, CLPP 
was immunolocalized in granulosa cells and oocytes. In the 
mouse inner ear, in the organ of Corti, CLPP is predomi-
nantly localized in supporting cells and weakly in adjacent 
sensory hair cells at postnatal day 3 (Jenkinson et al. 2013) 
even though hair cells have abundant mitochondria (Weaver 
and Schweitzer 1994). The functional significance of the 
cell-type restricted expression of CLPP and the limited phe-
notypic consequence of diminished CLPP activity is not well 
understood in human but has been explored in Clpp mutant 
mice (Gispert et al. 2013).
Three different CLPP deficient mouse models have been 
reported, two independent gene-traps in intron 1 and intron 
2 (Gispert et al. 2013) and a conditional knockout via cre-
recombination mediated excision of floxed exons 3, 4 and 5 
(Szczepanowska et al. 2016). The phenotypes of these CLPP 
deficient mice show important differences in viability of 
adults for reasons not fully understood (Szczepanowska et al. 
2016). One study reported some postnatal lethality (Gispert 
et al. 2013) while for homozygous Clpp exon 3–5 deleted 
mice, no difference was observed for adult survival when 
compared to the wild type, although there was significant 
embryonic lethality (Szczepanowska et al. 2016). Males and 
females in both CLPP deficient mouse models are hearing 
impaired and sterile, suggesting a more careful evaluation 
of fertility status is warranted for deaf human males with 
biallelic variants of CLPP. There is one example of a deaf 
male proband homozygous for the p.C144R variant of CLPP 
who is azoospermic (Demain et al. 2017).
We used template-based molecular modelling to analyze 
the possible structural and functional impact of each of 
the ten reported and one novel missense variants of CLPP 
associated with Perrault syndrome (Fig. 1). Each mutant 
structural model was obtained using the X-ray structure of 
human CLPP (hCLPP; PDB id:1tg6) (Kang et al. 2004) as 
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template and structurally superimposed on the CLPP-CLPX 
complex from Neisseria meningitidis (PDB id: 6vfs) (Rip-
stein et al. 2020) to analyze the variant impact on the pro-
teolytic active complex formed by two heptameric CLPP 
rings bound to a CLPX pentamer. Four wild type residues 
(p.C86, p.T135, p.C144 and p.G162), mutated in human 
CLPP-associated Perrault syndrome (Fig. 1), have a cru-
cial role in different interacting networks. Their side chains 
establish key interactions with other residues where, or 
close to where, CLPX binds to CLPP. These are important 
contact regions as they are responsible for maintaining the 
3D-architecture of the CLPX binding site. For example, 
p.C86 takes part in an intra- and inter-protomeric network of 
residue-residue interactions located deep in the CLPP cav-
ity, which is abolished when the p.C86 is substituted with 
tyrosine (p.C86Y). p.T135 stabilizes the packing between 
two alpha-helices that face the cavity by stabilizing a set of 
hydrophobic contacts with its methyl group (Fig. 2). The 
substitution of p.T135 by a serine (p.T135S) removes this 
key methyl group, completely abolishing the hydrophobic 
interactions in this region. The p.G162 residue is located 
in a tightly packed region that involves the loop containing 
p.G162 itself and two beta-strands that shape CLPX bind-
ing site. The introduction of the larger serine residue at this 
position (p.G162S), induces allosteric clashes between the 
new side chain and the hydrophobic residues in the region in 
agreement with the previous work (Theunissen et al. 2016). 
The potential detrimental effect of these three substitu-
tions, p.C86Y, p.G162S and p.T135S, on the shape of the 
CLPX binding site are predicted to impair formation of the 
CLPP-CLPX active complex and consequently diminishing 
CLPP proteolytic function (Fig. 2). In contrast to p.C86, 
p.G162 and p.T135 residues, which are not located directly 
in the CLPX binding site, p.C144 faces the cavity where 
CLPX binds. The p.C144R substitution introduces a large, 
positively charged residue directly in the CLPX binding site 
that not only is predicted to change the volume available for 
CPLX to bind to CLPP but also the electrostatic potential 
of the pocket itself.
The substitutions p.P142L, p.T145P, p.C147S and 
p.I208M (Supplementary Fig.  2) have a more subtle 
impact on the structure, which is more difficult to relate to 
changes in CLPX binding or protease activity. We predict 
that p.P142L introduces a large hydrophobic residue that 
might change the local packing in agreement with pub-
lished speculation that this may affect CLPP-CLPX binding 
(Theunissen et al. 2016). The p.T145P substitution com-
pletely abolishes the local interacting network that involves 
a loop and two helices. Yet such a change is not predicted to 
affect CLPX binding but may induce a toxic-gain of protease 
activity (Brodie et al. 2018). p.C147S has a minimal struc-
tural impact which agrees with the fact that such a mutation 
does not affect CLPX binding or protease activity and may 
explain the mild symptoms observed in patients with this 
mutation (Brodie et al. 2018). The substitution of p.I208 
by a methionine that contains a larger side chain introduces 
steric clashes in a region (Brodie et al. 2018) and is close to 
the catalytic triad, possibly impacting the protease activity 
of the CLPP mutant.
While the variants p.C86Y, p.G162S, p.T135S and 
p.C144R misshape the CLPX binding site of CLPP, 
p.Y229D has severe structural impact as it affects different 
aspects of CLPP. p.Y229 is part of the interacting network 
located at the interface between CLPP protomers and is also 
close to the catalytic triad responsible of the protease activ-
ity of CLPP. The introduction of an aspartate at position 
229 may abolish the interactions at the interface between 
protomers destabilizing the formation of the heptameric ring 
of CLPP itself but it may also affect the relative orienta-
tion of the catalytic triad. These observations agree with the 
experiments of Brodie and co-authors in which p.Y229D not 
only affects the correct formation of the heptameric CLPP 
complex and subsequent CLPX binding but also decreases 
the protease activity of CLPP (Brodie et al. 2018). Consider-
ing that p.C86Y, p.G162S, p.T135S, p.P142L and p.C144R 
are each predicted to impair binding of CLPX to form a 
CLPP proteolytic active complex, we hypothesize that the 
missense-mutated CLPP may, nevertheless, still be avail-
able for a CLPX-independent “chemical activation” using 
small molecules such as imipridones. This family of com-
pounds, for instance ONC201, is used as chemical activators 
of CLPP as they induce similar structural changes in CLPP 
when CLPX binds to CLPP (Bonner et al. 2020). ONC201 
binds in the same CLPP cavity as CLPX (Ishizawa et al. 
2019) and it activates the CLPP proteolytic machinery, but 
without the need for CLPX and is already being used in 
the clinic as a cancer chemotherapeutic drug (Bonner et al. 
2020). We further speculate that imipridone compounds may 
improve hearing and fertility in a subset of Perrault syn-
drome patients. One prerequisite for this potential therapeu-
tic intervention to work in patients with an amino acid sub-
stitution of CLPP predicted to abolish the binding of CLPX 
to CLPP, is a lack of secondary structural degeneration of 
the inner ear at the time of treatment. In addition, females 
should have intact ovaries.
ERAL1
ERAL1 is a nuclear gene that encodes a 48 kDa mitochon-
drial protein that is indispensable for the assembly of the 
12S ribosomal RNA subunit. Exome sequencing of a male 
and three females of Dutch ancestry revealed a homozygous 
missense variant (c.707A > T; p.N236I) of ERAL1 (Era-like 
12S mitochondrial rRNA chaperone) (Fig. 1) associated 
with Perrault syndrome (Chatzispyrou et  al. 2017). All 





sensorineural hearing loss. There was a spectrum of ovar-
ian insufficiency in the females from early menopause at age 
27 years to complete ovarian dysgenesis. This c.707A > T 
is a founder variant with an allele frequency of 4.6% (49 
heterozygotes of 530 individuals) in a Dutch isolate (Chatz-
ispyrou et al. 2017). To date no other variants in ERAL1 
have been reported to be associated with Perrault syndrome. 
However, the authors of the original discovery paper pro-
vided convincing supporting experimental data for the 
pathogenicity of p.N236I damaging the normal function of 
ERAL1 (Chatzispyrou et al. 2017). The asparagine at resi-
due 236 is evolutionarily conserved and directly interacts 
with GTP. Cultured skin fibroblasts from one of the Perrault 
subjects displayed decreased levels of ERAL1 protein com-
pared to control fibroblasts, impaired assembly of the small 
28S ribosomal subunit and a 30 to 40% reduced level of 
proteins composing the small 28S mitochondrial ribosomal 
subunit. Excess expression of ERAL1 in these fibroblasts 
restores 12S ribosomal RNA levels. RNAi knockdown in 
the C. elegans orthologue of human ERAL1 induced reduced 
fecundity. Moreover, in the wild type mouse, the necessary 
and timely normal withdrawal of ERAL1 from the matur-
ing mitochondrial ribosomes requires CLPX and CLPP 
(CLPXP) proteolytic function (Szczepanowska et al. 2016). 
In mouse, the absence of CLPP proteolysis of ERAL1 results 
in its increased level and ERAL1 remains abnormally asso-
ciated with mitochondrial ribosomes preventing maturation 
to functional mitoribosomes. Both male and female CLPP 
deficient mice have respiratory chain deficiency, are reduced 
in size and are sterile (Gispert et al. 2013; Szczepanowska 
et al. 2016). When CLPP function is deficient, there is excess 
ERAL1 expression resulting in reduced mitochondrial pro-
tein synthesis. Collectively, these observations point to a 
breakdown in mitochondrial protein homeostasis as the pre-
dominant pathogenic hypothesis that connects a spectrum 
of variants of ERAL1, CLPP, LARS2 and HARS2 with the 
Perrault syndrome phenotype (Szczepanowska et al. 2016).
GGPS1
GGPS1 encodes a cytosolic and perhaps mitochondrial, 
geranylgeranyl diphosphate (GGPP) synthase. There appears 
to be some colocalization of GGPS1 with ATP synthase 
beta, a marker for mitochondria (Foley et  al. 2020). In 
11 patients of six unrelated families, Foley and coauthors 
described a new syndrome manifesting with early-onset, 
progressive muscular dystrophy, likely congenital deafness 
and POI with a menopausal level of FSH (Foley et al. 2020). 
The fertility status of five deaf males in these families is 
unknown. GGPS1 is expressed in testes and reduced expres-
sion of GGPS1 is associated with infertility in men (Bae 
et al. 2019; Foley et al. 2020; Wang et al. 2013). Eight of the 
11 affected subjects had short stature and a failure to thrive. 
Exome sequencing revealed biallelic missense variants in 
GGPS1 (Fig. 1). Two unrelated individuals with Perrault 
syndrome were reported as homozygous for missense vari-
ants (R261H and N90S) of GGPS1 (Tucker et al. 2020). The 
substitutions of GGPS1 associated with Perrault syndrome 
are not located in the catalytic domain and are suggested to 
alter interactions with predicted, although presently unre-
ported, binding partners important for function of GGPS1 
in ovaries, ears and muscle (Foley et al. 2020).
LARS2
LARS2 and HARS2 are nuclear genes that encode mitochon-
drial amino acyl tRNA synthetases. To date, nine variants 
of LARS2 have been reported associated with Perrault syn-
drome (Fig. 1). LARS2 is located on human chromosome 
3p21.31 and encodes mitochondrial leucyl aminoacyl tRNA 
synthetase (Konovalova and Tyynismaa 2013). In the dis-
covery paper, the female probands had hearing loss and POI 
with normal 46, XX karyotypes. After exome sequencing, 
a homozygous missense variant (p.T522N) was segregating 
in one consanguineous family. The affected individuals in 
the other family have a compound heterozygous genotype 
for a p.T629M substitution and, in trans, a frameshift allele 
of LARS2 (c.1077delT; p.I360Ffs*15) (Fig. 1). The three 
variants of LARS2 are predicted to be damaging (Pierce et al. 
2013). At the age of 8 years, one of the probands presented 
with mild to moderate hearing loss, which was more severe 
at low frequencies (upsloping audiogram) and rapidly pro-
gressed from severe to profound deafness by 17 years of age 
at which time she was diagnosed with primary amenorrhea, 
post-menopausal high levels of LH and FSH. By ultrasound, 
her ovaries were not visualized (Pierce et al. 2013). When 
a truncated LARS2 protein is expressed in C. elegans, the 
Fig. 2  Structural models of amino acid substitutions of CLPP protein 
associated with Perrault syndrome. a Human CLPP X-ray structure 
without a ligand bound (apo) and with ONC201 bound (CLPP ring1) 
superimposed on the CLPP-CLPX complex formed by two CLPP 
rings and one heptamer of CLPX. ONC201 is shown as sticks in mus-
tard color and the CLPP heptamer corresponding to the apo structure. 
CLPP and CLPX are represented as cartoon where the superimposed 
apo CLPP (ring 1) is highlighted in a different color per protomer, 
while the remainder CLPP heptamer (ring2) and the CLPX pen-
tamer (corresponding to the CLPP-CLPX structure) are gray and red 
colored. The C-alphas of the residues mutated in Perrault syndrome 
are shown as spheres only in one of the CLPP protomers (green) 
where the residues in or close to the CLPX binding site are dark-
green colored. b Structural comparison of the interacting networks 
where C86, T135, C144 G162 and Y229 participate in the WT and 
the corresponding modelled variant. As before, the model of each 
mutant was structurally superimposed on the CLPP-CLPX complex. 
The interactions between residues are shown as dashed lines and the 




worms are sterile due to lack of functional germ cells (Lee 
et al. 2003; Pierce et al. 2013).
A non‐consanguineous British family presenting with 
hearing loss and infertility was ascertained and found to 
be segregating compound heterozygous variants of LARS2 
(c.1565C > A, p.T522N and a novel LARS2: c.351G > C 
p.M117I) (Demain et al. 2017). The proband and an affected 
male sibling had bilateral severe to profound hearing loss. 
The proband presented with oligomenorrhea and a 46, XX 
karyotype. Her ovaries and uterus were structurally normal 
but small. Hormone levels of the affected male were in the 
normal range, but he presented with hypospadias without 
other urogenital abnormalities. Both siblings had mild 
dysmorphic features, low set ears but without other neu-
rological features (Demain et al. 2017). Additionally, two 
variants of LARS2 (c.899C > T, p.T300M and c.1912G > A, 
p.E638K) in compound heterozygosity were reported in two 
affected siblings. The family was ascertained in Italy and the 
proband had congenital profound hearing loss, but a normal 
menarche at age 13 and premature menopause at the age of 
28 years (Solda et al. 2016).
HARS2
The HARS1 gene encodes the cytoplasmic histidyl aminoa-
cyl tRNA synthetase while the closely linked head-to-head 
HARS2 gene encodes the mitochondrial histidyl aminoacyl 
tRNA synthetase. A family was ascertained with five sib-
lings, three females presenting with Type 1 Perrault syn-
drome and two deaf males. Genome-wide linkage analy-
sis, followed by positional cloning and Sanger sequence 
screening of 58 candidate genes in a 4.1 Mb interval on 
human chromosome 5q31 identified two missense variants 
(p.V368L and p.L200V) of HARS2 (Pierce et al. 2011). 
Lymphoblasts mRNA was evaluated from one of the affected 
females. The p.L200V substitution created an alternative 
splice site deleting 12 amino acid residues in-frame (Pierce 
et al. 2011). Both wild type residues of human HARS2 are 
conserved in the yeast orthologue. In comparison to wild 
type, HARS2 purified protein with either the leucine-368 or 
valine-200 have reduced enzymatic aminoacylation activity 
(Pierce et al. 2011). Together with additional experimental 
data, a convincing case was made that the variants of HARS2 
are associated with Perrault syndrome. A total of 13 vari-
ants of HARS2 associated with Perrault syndrome have been 
reported (Fig. 1).
HSD17B4
The nascent HSD17B4 protein is an 80 kDa 736-amino 
acid polypeptide that is imported into the peroxisome and 
proteolytically cleaved into 35 kD and 45 kDa monomers. 
The monomers then assemble into two distinct homodimeric 
enzymes, respectively, a 17 beta-hydroxysteroid dehydroge-
nase catalyzing the beta-oxidation of very long-chain fatty 
acids (VLCFA) and a fatty acyl-CoA-hydratase (Baes et al. 
2000; Leenders et al. 1996). Two deaf sisters were reported 
to have short stature, intellectual disability, peripheral motor 
neuropathy and ovarian dysgenesis (Fiumara et al. 2004). 
By exome sequencing, the authors identified compound het-
erozygous variants (p.Y217C and p.Y568X) of HSD17B4, 
which was the first gene associated with Perrault syndrome 
(Pierce et al. 2010). HSD17B4 expresses multiple spliced 
transcripts. Prior to post-translation proteolytic cleavage, the 
longest HSD17B4 protein has two independent enzymatic 
active domains that catalyze two steps in the beta-oxidation 
of fatty acids (de Launoit and Adamski 1999) and at the 
carboxy-terminus there is a peroxisome targeting signal (ala-
nine-lysine-isoleucine). Peroxisomes are organelles special-
ized for catabolism of hydrogen peroxide and oxidation of 
fatty acids (Fujiki et al. 2020; Violante et al. 2019).
There are other cases of Type 2 Perrault syndrome associ-
ated with variants of HSD17B4 (Chen et al. 2017; Demain 
et al. 2017; Kim et al. 2013) for a total of 10 variants (Fig. 1). 
One or both of the Perrault syndrome-associated HSD17B4 
variants are located in 9 of its 24 exons and at least one of 
the two alleles results in an amino acid substitution in one 
of the two catalytic domains of the two HSD17B4 proteins. 
However, the majority of pathogenic variants of HSD17B4 
are not associated with Perrault syndrome, but rather with 
DBP deficiency (D-bifunctional protein), characterized by 
a severe spectrum of life-limiting neurological symptoms 
usually fatal in the first few years after birth. DBP deficiency 
was first described in two patients (Suzuki et al. 1997) exhib-
iting reduced fertility, seizures, hypotonia, loss of vision due 
to retinal atrophy and mild to severe hearing loss. Variants 
of HSD17B4 associated with Perrault syndrome (Fig. 1) are 
on the mild side of the continuum with more severe DBP-
deficiency peroxisomal disorders.
TWNK
TWINKLE is a nuclear encoded hexameric mitochon-
drial protein with primase and helicase domains essential 
for replication of the mitochondrial chromosome (Morino 
et al. 2014). Two unrelated families of Japanese ancestry 
were reported to be segregating hearing loss and ovarian 
dysgenesis as well as multiple neurological impairment, 
including progressive ataxia, axonal neuropathy, hypore-
flexia, and abnormal eye movements. Exome sequencing of 
the two affected females in each family identified a total of 
four different pathogenic variants of TWNK (c10orf2). Only 
12 variants of TWNK have been reported to date which are 
responsible for Perrault syndrome (Fig. 1) (Gotta et al. 2020; 
Oldak et al. 2017). There are additional recessive variants of 
TWNK that are associated with mtDNA depletion syndrome 
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7 (infantile-onset spinocerebellar ataxia) while progressive 
external ophthalmoplegia type 3 (PEOA3, OMIM 609286) is 
due to a different set of dominant variants of TWNK (Tyyn-
ismaa et al. 2005).
RNA‑Seq of Perrault syndrome genes 
demonstrates prominent expression 
in spiral ganglion neurons
Heatmaps of gene expression across cochlear cell types 
were generated by utilizing single-nucleus RNA-Seq data-
sets from the P30 adult mouse SV (Gu et al. 2020), single-
cell RNA-Seq datasets from P7 mouse organ of Corti (Kolla 
et al. 2020) and P25-P27 mouse spiral ganglion neurons 
(SGN) (Shrestha et al. 2018) (Fig. 3a–c). In mouse, hair cells 
exist in a postmitotic state by P0. By postnatal day seven 
(P7), hair cells are at an early stage of maturity. The onset 
of hearing in mouse occurs at approximately P12. Datasets 
were normalized using a previously published analysis pipe-
line (Gu et al. 2020). All data were scaled between 0 and 1 
using min–max scaling as described (Gu et al. 2020). Low 
levels of expression of Perrault syndrome-associated genes 
can be seen in the stria vascularis (SV) cell types includ-
ing marginal, intermediate, basal and spindle cells as well 
as the adjacent root cells and Reissner’s cell type (Fig. 3a). 
Similarly, from the P7 organ of Corti single-cell RNA-Seq 
dataset, Perrault syndrome-associated gene expression 
in inner and outer hair cells, pillar and Deiters cells show 
relatively low levels of expression of these genes except for 
Clpp, which exhibits broad low-level expression across all 
of these cell types (Fig. 3b) compared to spiral ganglion 
neurons (SGN) (Fig. 3c). Perrault syndrome-associated 
genes are ubiquitously and prominently expressed across 
all type 1 SGNs (1A, 1B, 1C) (Shrestha et al. 2018). With 
the exception of Eral1, similar expression of these genes was 
noted in type 2 SGNs. However, there are only seven type 
2 SGN single cell transcriptomes included in the dataset 
making it difficult to draw conclusions about the expression 
of these genes in type 2 SGNs. These data are consistent 
with Perrault syndrome gene expression in regions of the 
adult mouse cochlea (organ of Corti, lateral wall, and spiral 
ganglion region) from laser-capture micro-dissected adult 
mouse tissues (Nishio et al. 2017). Twnk was not found to be 
expressed amongst type 1 SGNs but is expressed in the bulk 
RNA-Seq of P8 glial cells reported by  Li and colleagues (Li 
et al. 2020) visualized in the “Neuron” datasets in gEAR 
(https:// umgear. org/p? l= fee36 0e8).
From the combined datasets in these reported RNAseq 
studies (Fig. 3), we hypothesize a common cellular patho-
physiology for Perrault syndrome. We propose that the 
pathogenic variants of the Perrault syndrome-associated 
genes discussed in this review damage essential processes in 
spiral ganglion neurons resulting in deafness. This hypoth-
esis rests on the assumption, perhaps simplistic, that a dis-
tinct high level of expression in a cell type of a complex 
organ, such as the inner ear, points towards the cell type 
where a gene serves an essential function. These RNA-Seq 
data also suggest that rehabilitation with a hearing aid or 
cochlear implant (CI) might be problematic in some Per-
rault syndrome individuals if spiral ganglion neurons are not 
functioning properly. Spiral ganglion neurons are necessary 
to transmit a CI-initiated electrical stimulation to the brain-
stem. Nevertheless, two recent reviews on this subject point 
to individuals with auditory neuropathy spectrum disorders 
(ANSD) who do benefit from cochlear implants (Eshraghi 
et al. 2020; Shearer and Hansen 2019). Benefit from a CI 
depends on the site and magnitude of the physiological 
lesion. Importantly, although these two reviews discussed 
results of cochlear implantation in ANSD, which is thought 
to be genetically heterogeneous, neither discussed the results 
of cochlear implantation in patients with genetic mutations 
in genes associated with Perrault syndrome. While data on 
CI outcomes in patients with Perrault syndrome is limited 
and mixed, some studies of patients with LARS2 variants 
indicated that these patients achieved expected hearing lev-
els from cochlear implantation (Carminho-Rodrigues et al. 
2020; Solda et al. 2016; van der Knaap et al. 2019). How-
ever, a patient was reported who failed to develop speech 
after receiving a cochlear implant at 1.5 years of age (van 
der Knaap et al. 2019). Thus, more detailed reporting of 
clinical outcomes with cochlear implantation are needed to 
identify whether specific genetic variants associated with 
Perrault syndrome will impact the ability of these patients 
to benefit from cochlear implantation. Examining the spiral 
ganglion neurons in the temporal bones from humans with 
Perrault syndrome may also help to resolve this question by 
identifying structures in the cochlea that have undergone 
degeneration, possibly revealing if and to what extent SGNs 
degenerate in the setting of Perrault syndrome.
Pleiotropic manifestations of variants 
in genes associated with Perrault syndrome
It is important to emphasize that more deleterious vari-
ants in some of the genes associated with Perrault syn-
drome can result in a more severe childhood onset clinical 
phenotype (Theunissen et al. 2016). Riley and coauthors 
reported biallelic variants of LARS2 in a neonate who died 
in the first few days of life with hydrops, lactic acidosis, 
sideroblastic anemia (HLASA), and multisystem failure 
(Riley et al. 2016). One variant in the child was shown to 
have reduced aminoacylation activity (Riley et al. 2016). 
These investigators have recently expanded this obser-
vation of severe phenotypes associated with variants of 
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LARS2, with the description now of three patients with a 
HLASA‐like phenotype, an individual with Perrault syn-
drome whose affected siblings also had leukodystrophy, 
and an individual with a reversible mitochondrial myo-
pathy, lactic acidosis, and developmental delay (Riley 
et al. 2020). Leukodystrophy appears to be an emerging 
clinical phenotype caused by a number of variants in genes 
associated with Perrault syndrome. Many individuals with 
variants of LARS2 and CLPP have been described with 
white matter changes and neurological features includ-
ing ataxia, intellectual disability and epilepsy (Theunis-
sen et al. 2016; van der Knaap et al. 2019). Importantly, 
complete loss of function of the genes associated with 
Perrault syndrome is likely to be incompatible with life 






When the clinical phenotypes of the published individu-
als with Perrault syndrome are collated some interesting 
genotype–phenotype correlations emerge (Table 1 and 
Supplementary Table 2). Variable degrees of SNHL are 
found in affected individuals, ranging from mild-moder-
ate to profound and associated with variants in all of the 
genes, except for CLPP where the majority of individu-
als have severe to profound hearing loss. Variants of the 
Perrault syndrome genes, except for HARS2 and ERAL1, 
have been associated with evidence of neurological seque-
lae and have all resulted in more severe childhood onset 
phenotypes. This is most striking for TWNK, HSD17B4, 
CLPP and GGPS1. It is difficult to draw conclusions about 
ERAL1 due to the report of only a single disease associ-
ated variant, but biallelic variants in HARS2 do not appear 
to result in neurological problems. Therefore, based on 
the classification into Type 1 and Type 2, it appears that 
variants in all of the Perrault syndrome associated genes 
can result in either form, except for HARS2 and possibly 
ERAL1. Consistent with ascertainment biases in novel 
disease gene discovery, variants in the more recently 
described Perrault syndrome-associated genes, TWNK, 
ERAL1 and GGPS1 have been described predominantly 
in females with ovarian dysfunction as well as SNHL. It is 
likely that more males with hearing loss will be identified 
with variants in these genes.
Coincidental Perrault syndrome
There are many non-genetic causes of permanent deafness 
including ototoxic drugs and viral infections (Kros and Steyger 
2019). Nongenetic etiologies such as chemotherapy and micro-
bial infections also cause infertility (Cohen et al. 2014; Grosse 
et al. 2008). Some sporadic cases of Perrault syndrome may be 
caused in part or entirely to nongenetic etiologies. Addition-
ally, there are hundreds of genes with variants associated with 
just deafness (Griffith and Friedman 2016) and similarly there 
are many genetic variants associated with infertility (Imtiaz 
et al. 2018; Kosova et al. 2012; Zorrilla and Yatsenko 2013).
John M. Opitz suggested there may be coincidental syn-
dromes caused by the co-occurrence of more than one etiology 
for a multisystem disorder with features taken together that 
define a distinct syndrome (Opitz et al. 1979), for example, 
the combination of POI and deafness. We reported such a case 
of coincidental Perrault syndrome in a consanguineous fam-
ily (Faridi et al. 2017). The 24-year-old proband was deaf, 
presented with oligomenorrhea and had an endocrine profile 
in the reference range for post-menopausal women consistent 
with hypergonadotropic hypogonadism. After exome sequenc-
ing, the POI was associated with a homozygous frameshift 
variant of SGO2 (previous gene symbol, SGOL2). So far, there 
is only one homozygous loss of function variant of SGO2 
(c.1453_1454delGA, p.E485Kfs*5) reported in the Human 
Gene Mutation Database (HGMD). In mouse, shugoshin 2a 
encoded by Sgol2a, the orthologue of human SGO2, is essen-
tial for meiosis and its absence causes infertility in males and 
females (Llano et al. 2008; Salic et al. 2004).
While the proband’s infertility was likely due to homozy-
gous null alleles of SGO2, the profound deafness was associ-
ated with homozygosity for pathogenic variants of CLDN14 
encoding claudin 14, a member of the claudin family of tight 
junctions (Wilcox et al. 2001). In mouse, a homozygous 
knockout mutation of Cldn14 also causes deafness by partial 
loss of the cation-restrictive paracellular barrier in the organ 
of Corti and the subsequent post-natal death of hair cells (Ben-
Yosef et al. 2003). Perhaps there are other unexplained cases 
of deafness and infertility resulting from coincidental Perrault 
syndrome. Importantly, individuals classified as Perrault syn-
drome who subsequently turn out to have two independent 
genetic disorders, one causing deafness and the other POI, 
would benefit from counseling that their clinical phenotype is 
the result of more than one monogenic disorder.
Fig. 3  Cochlear localization of Perrault syndrome genes using single-
cell and single-nucleus RNA-Seq datasets to pinpoint the possible 
cell types associated with deafness in this genetically heterogenous 
disorder. Single-cell RNA-Seq datasets from the P7 mouse organ of 
Corti (Kolla et al. 2020) and P25-27 mouse spiral ganglion neurons 
(Shrestha et  al. 2018) along with a published P30 adult mouse stria 
vascularis single-nucleus RNA-seq dataset (Gu et al. 2020) were uti-
lized to identify Perrault gene expression levels in the cell types of 
the inner ear. Heatmaps display Perrault syndrome-associated genes 
along the vertical axis and cell types are grouped along the horizontal 
axis. Expression is in normalized counts scaled from 0 to 1. Higher 
expression of a gene of interest is indicated by an increasing darker 
purple color. a Heatmap of Perrault syndrome gene expression among 
P30 stria vascularis cell types including marginal, intermediate, basal, 
spindle, root, and Reissner’s membrane cells, as well as macrophages. 
Note the low level of expression of these genes across the stria vas-
cularis. b Heatmap of Perrault syndrome gene expression among 
cell types in the P7 organ of Corti including inner hair cells (IHC), 
outer hair cells (OHC), pillar cells, and Deiters cells. Note the low 
level of expression of Clpp in these cell types in the organ of Corti. 
c Heatmap of Perrault syndrome gene expression among type 1 (1A, 
1B, and 1C) and type 2 spiral ganglion neurons (SGN). Note that the 
prominent expression of these Perrault syndrome-associated genes 
across all SGN types suggests the hypothesis that the hearing loss for 





Features of Perrault syndrome can be part 
of a multisystem disorder
RMND1 is a nuclear encoded mitochondrial protein involved 
in the translation of mitochondrial encoded respiratory chain 
proteins (Broenen et al. 2019). Biallelic variants in RMND1 
were initially described to result in a severe childhood disor-
der of encephalopathy associated with defective mitochondrial 
translation (Janer et al. 2012). Subsequent reports expanded the 
phenotype to include hearing loss and renal defects as key clini-
cal features (Ng et al. 2016). We described a family segregating 
a known pathogenic variant in RMND1: c.713A > G, p.N238S 
with clinical features of Perrault syndrome and distal renal 
tubular acidosis (Demain et al. 2018) (Fig. 1). This association 
between RMND1 and features of Perrault syndrome with renal 
impairment has been replicated recently (Ozieblo et al. 2020).
Biallelic loss of function variants in the gene PEX1 and PEX6 
are associated with the fatal peroxisomal disorder Zellweger syn-
drome. Hypomorphic variants in these genes result in a milder 
phenotype characterized by amelogenesis imperfecta, retinal 
dysfunction and SNHL (Ratbi et al. 2015). Recently an indi-
vidual with SNHL, POI, retinitis pigmentosa and leukodystophy 
was reported to be compound heterozygous for c.2356C > T, 
p.R786W and c.371 T > C, p.L124P in PEX6 (Tucker et al. 2020). 
This further shows the clinical overlap between peroxisomal dys-
function including HSD17B4 and dysfunction of mitochondrial 
translation evident in other individuals with Perrault syndrome. 
In light of this finding, it will be important to assess the ovarian 
reserve in woman identified to have biallelic hypomorphic vari-
ants in PEX1, PEX6 and other peroxisomal genes.
Therapeutic options
Treatment for individuals with Perrault syndrome is sympto-
matic. Presently, there are no specific therapeutic approaches 
based on genotype. Dependent on the degree of impairment, 
restoring hearing capacity is either through hearing aids or 
cochlear implantation. Anecdotal evidence suggests that coch-
lear implantation is effective. Eventually otolaryngologists will 
be able to provide personalized gene therapies to correct either 
one or both copies of the recessive variant allele or provide a 
wild-type transgene to compensate for the difunctional endog-
enous gene. A pediatric endocrinologist may treat the primary 
amenorrhea with estrogen replacement to induce secondary 
sexual characteristics. The degree of residual ovarian function 
in women with POI is variable and despite reduced ovarian 
reserve, some women with Perrault syndrome may experi-
ence spontaneous ovulation, resulting in conception and live 
birth (Jenkinson et al. 2013). In vitro fertilization (IVF) with 
autologous oocytes is an effective treatment for women with 
POI when the residual ovarian reserve is sufficient for ovarian 
stimulation (Chae-Kim and Gavrilova-Jordan 2018). Oocyte 
cryopreservation should be considered in young women with 
Perrault syndrome with ovarian reserve who wish to defer 
starting a family. In contrast, women with follicular depletion, 
diminished ovarian reserve and clinical hypoestrogenism can 
benefit from IVF with donor oocytes.
Conclusions
Perrault syndrome is a complex genetically and clinically 
heterogeneous condition. Recent work has expanded the 
clinical phenotype to encompass more severe childhood 
onset presentations with multisystem metabolic and neuro-
logical features. The dysfunction of mitochondrial protein 
translation underlying the pathogenesis of most cases of Per-
rault syndrome provides important insight into the role of 
this pathway in the normal development of hearing function 
and offers opportunities for therapeutic intervention.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s00439- 021- 02319-7.
Table 1  Summary of 
clinical features in published 
molecularly defined individuals 
with Perrault syndrome
m-m mild to moderate; m-s moderate to severe; s-p severe to profound sensorineural hearing loss. NR not 
recorded
Gene Sex (Female:Male) Degree of sensorineural 








CLPP 15:10 0:4:13 (8 NR) 12:13 13:12
ERAL1 3:1 NR 3:1 0:4
GGPS1 3:0 NR 2:1 3:0
HARS2 9:8 (1 NR) 4:6:8 8:10 0:18
HSD17B4 5:2 2:4:1 3:4 6:1
LARS2 13:10 6:3:7 (5 NR) 11:12 5:18
RMND1 3:0 0:1:2 3:0 0:3
TWNK (C10orf2) 5:0 1:1:1 (2 NR) 5:0 5:0
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